TY - JOUR
T1 - A novel cell-free method to culture Schistosoma mansoni from cercariae to juvenile worm stages for in vitro drug testing
AU - Frahm, Sören
AU - Anisuzzaman, Anisuzzaman
AU - Prodjinotho, Fabien
AU - Vejzagić, Nermina
AU - Verschoor, Admar
AU - Prazeres da Costa, Clarissa
N1 - Funding Information:
The study was partially funded by an Alexander von Humboldt fellowship awarded to AA and CPdC. (https://www.humboldt-foundation.de). CPdC was further supported by projects CO 1469/8-1 and CO 1469/10-1 of the German Research Foundation (DFG). AV was supported by Collaborative Research Center SFB 914 (Project B04) and International Research Training Group IRTG 1911 (Project B09) of the German Research Foundation (DFG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank Prof J. Keiser for a thorough insight into the process of transformation and schistosomula cultivation. Prof. K. Ulm for advice concerning the statistical analysis of the data, Ulla Henn and Stephanie Fetzer for the maintenance of the life cycle and Laura Hunt for careful proof-reading of the manuscript. B. glabrata snails provided by the NIAID Schistosomiasis Resource Center of the Biomedical Research Institute (Rockville, MD) through NIH-NIAID Contract HHSN272201700014I for distribution through BEI Resources.
Publisher Copyright:
© 2019 Frahm et al.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/1/28
Y1 - 2019/1/28
N2 - Background: The arsenal in anthelminthic treatment against schistosomiasis is limited and relies almost exclusively on a single drug, praziquantel (PZQ). Thus, resistance to PZQ could constitute a major threat. Even though PZQ is potent in killing adult worms, its activity against earlier stages is limited. Current in vitro drug screening strategies depend on newly transformed schistosomula (NTS) for initial hit identification, thereby limiting sensitivity to new compounds predominantly active in later developmental stages. Therefore, the aim of this study was to establish a highly standardized, straightforward and reliable culture method to generate and maintain advanced larval stages in vitro. We present here how this method can be a valuable tool to test drug efficacy at each intermediate larval stage, reducing the reliance on animal use (3Rs). Methodology/Principal findings: Cercariae were mechanically transformed into skin-stage (SkS) schistosomula and successfully cultured for up to four weeks with no loss in viability in a commercially available medium. Under these serum- and cell-free conditions, development halted at the lung-stage (LuS). However, the addition of human serum (HSe) propelled further development into liver stage (LiS) worms within eight weeks. Skin and lung stages, as well as LiS, were submitted to 96-well drug screening assays using known anti-schistosomal compounds such as PZQ, oxamniquine (OXM), mefloquine (MFQ) and artemether (ART). Our findings showed stage-dependent differences in larval susceptibility to these compounds. Conclusion: With this robust and highly standardized in vitro assay, important developmental stages of S. mansoni up to LiS worms can be generated and maintained over prolonged periods of time. The phenotype of LiS worms, when exposed to reference drugs, was comparable to most previously published works for ex vivo harvested adult worms. Therefore, this in vitro assay can help reduce reliance on animal experiments in search for new anti-schistosomal drugs.
AB - Background: The arsenal in anthelminthic treatment against schistosomiasis is limited and relies almost exclusively on a single drug, praziquantel (PZQ). Thus, resistance to PZQ could constitute a major threat. Even though PZQ is potent in killing adult worms, its activity against earlier stages is limited. Current in vitro drug screening strategies depend on newly transformed schistosomula (NTS) for initial hit identification, thereby limiting sensitivity to new compounds predominantly active in later developmental stages. Therefore, the aim of this study was to establish a highly standardized, straightforward and reliable culture method to generate and maintain advanced larval stages in vitro. We present here how this method can be a valuable tool to test drug efficacy at each intermediate larval stage, reducing the reliance on animal use (3Rs). Methodology/Principal findings: Cercariae were mechanically transformed into skin-stage (SkS) schistosomula and successfully cultured for up to four weeks with no loss in viability in a commercially available medium. Under these serum- and cell-free conditions, development halted at the lung-stage (LuS). However, the addition of human serum (HSe) propelled further development into liver stage (LiS) worms within eight weeks. Skin and lung stages, as well as LiS, were submitted to 96-well drug screening assays using known anti-schistosomal compounds such as PZQ, oxamniquine (OXM), mefloquine (MFQ) and artemether (ART). Our findings showed stage-dependent differences in larval susceptibility to these compounds. Conclusion: With this robust and highly standardized in vitro assay, important developmental stages of S. mansoni up to LiS worms can be generated and maintained over prolonged periods of time. The phenotype of LiS worms, when exposed to reference drugs, was comparable to most previously published works for ex vivo harvested adult worms. Therefore, this in vitro assay can help reduce reliance on animal experiments in search for new anti-schistosomal drugs.
UR - http://www.scopus.com/inward/record.url?scp=85061598956&partnerID=8YFLogxK
U2 - 10.1371/journal.pntd.0006590
DO - 10.1371/journal.pntd.0006590
M3 - Journal articles
C2 - 30689639
AN - SCOPUS:85061598956
SN - 1935-2727
VL - 13
JO - PLoS Neglected Tropical Diseases
JF - PLoS Neglected Tropical Diseases
IS - 1
M1 - e0006590
ER -